Venkata Sushma Chamarthi

Dr. Venkata Sushma Chamarthi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in Obesity Pillars
Verified
Journal Article
Open access
VCVenkata Sushma Chamarthi
Venkata Sushma Chamarthi
Pallavi ShirsatPallavi Shirsat
Pallavi Shirsat
KSKunal Sonavane
Kunal Sonavane
SPSaketh Parsi
Saketh Parsi
URUsha Ravi
Usha Ravi
SRSarah Ro
Sarah Ro
Ultra-processed foods (UPFs) have become increasingly incorporated into pediatric diets, accounting for approximately 67 % of the total energy consumption in United States (US) children. Manufactured through industrial processing and enriched with excess sugars, unhealthy fats, and sodium, while lacking essential nutrients, UPFs present a substantial public health concern. We aimed to conduct a comprehensive review of the impact of UPFs on pediatric health. We reviewed the effects of UPF on pediatric health using data from observational studies, systematic reviews, and policy reports. Our review explored the social, environmental, and economic drivers of UPF consumption, associated health consequences, and proposed mitigation strategies. We also examined National Health and Nutrition Examination Survey (NHANES) data, the 2025 US Dietary Guidelines Advisory Committee’s (USDA) report, and the Make America Healthy Again (MAHA) commission findings. UPF intake has dramatically increased during early childhood, with toddlers and school-aged children obtaining 47 % and 59.4 % of their daily calories, respectively, from UPFs. Higher consumption is linked to pediatric obesity, cardiometabolic risks such as insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD), mental health concerns, and gut microbiome disruption. Early-life exposure to UPFs can establish unhealthy dietary patterns that persist into adulthood, raising the risk of chronic disease. Greater UPF consumption is often observed among lower-income families, highlighting a key health disparity. UPF consumption is a modifiable risk factor for non-communicable diseases in children. Addressing it requires urgent, coordinated action at multiple levels. Strategies include UPF and sugar-sweetened beverage screening during well-child visits, policy restrictions on food marketing, clearer nutrition labeling, healthier school meals, and personalized family-centered dietary counseling. Clinicians need standardized tools and training to counsel families effectively. Policy initiatives should prioritize prevention-focused measures to protect children's health.

Verified
Journal Article
Open access
PDF file
Pallavi ShirsatPallavi Shirsat
Pallavi Shirsat
MBMalavika Balachandran
Malavika Balachandran
VCVenkata Sushma Chamarthi
Venkata Sushma Chamarthi
KSKunal Sonavane
Kunal Sonavane
Obesity is a significant public health crisis with increasing rates worldwide. Chronic kidney disease (CKD) has also emerged as a leading cause of death worldwide. This review explores the intricate connection between obesity and CKD, discussing the underlying biological mechanisms, clinical consequences of their coexistence, and strategies for evidence-based management. We conducted an extensive literature review of peer-reviewed studies examining obesity–CKD relationships, including epidemiological studies, mechanistic research, clinical trials, and meta-analyses from major medical databases. Obesity serves as both a risk factor for de novo CKD development and a paradoxical protective factor observed in some studies of advanced CKD, particularly in dialysis populations. This review synthesizes current evidence on obesity-related glomerulopathy, the impact of obesity on CKD progression to end-stage renal disease, and the phenomenon known as the “obesity paradox”. Management approaches, including lifestyle interventions, pharmacological treatments, and bariatric surgery, show varying efficacy across different CKD stages. The multifaceted relationship between obesity and CKD necessitates individualized, multidisciplinary approaches to optimize patient outcomes while addressing the unique challenges presented by this complex comorbidity. Early intervention in obese patients may prevent CKD development, while careful management is required in advanced CKD stages where the obesity paradox may confer survival benefits.

22 October 2025 in The International Journal of Psychiatry in Medicine
Verified
Journal Article
Closed access
VCVenkata Sushma Chamarthi
Venkata Sushma Chamarthi
PDPiyush Das
Piyush Das
Rahul KashyapRahul Kashyap
Rahul Kashyap
Objective: With the rapid adoption of artificial intelligence (AI) technologies by adolescents, the impact on their mental health is of critical concern. This article examines the emerging phenomenon of AI-related psychosis, which can be defined as new-onset or exacerbated psychotic experiences associated with generative AI platforms, such as chatbots, avatars, and virtual agents like Siri and Alexa. Method: Narrative review and perspective. Results: Adolescents are particularly susceptible due to ongoing neurodevelopmental immaturity, including underdeveloped prefrontal regulatory circuits and heightened limbic system reactivity, which may impair emotional regulation and reality testing. Combined with extensive digital engagement, these factors increase vulnerability to psychotic experiences in response to AI interactions. There are behavioral risk factors, online habits, and neurobiological susceptibilities that may predispose adolescents to such experiences. In addition, implications are outlined for healthcare providers, including an emphasis on proactive screening, digital literacy education, and early intervention strategies. Clinical approaches to recognize and manage AI-related mental health risks in adolescents are also proposed. Conclusions: A multidisciplinary response by clinicians, educators, developers, and policymakers is needed to guide ethical AI design and safeguard the well-being of adolescents in today's digital environment.

11 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SPSaketh Parsi
Saketh Parsi
KSKunal Sonavane
Kunal Sonavane
URUsha Ravi
Usha Ravi
Pallavi ShirsatPallavi Shirsat
Pallavi Shirsat
VCVenkata Sushma Chamarthi
Venkata Sushma Chamarthi
Rahul KashyapRahul Kashyap
Rahul Kashyap
Background/Objectives: Sodium glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated a reduction in heart failure (HF) hospitalizations in HF patients and decreased recurrence of atrial fibrillation (AF), including in those who have undergone catheter ablation (CA). The effects of SGLT2i are likely due to suppression of the renin–angiotensin–aldosterone system, reduction in oxidative stress with subsequent improvement in myocardial efficiency, and attenuation of cardiac remodeling. We aim to present the effects of SGLT2i on AF recurrence in patients who have undergone CA for AF. Methods: This is a systematic review and meta-analysis of randomized controlled trials (RCTs) and retrospective studies evaluating the effect of SGLT2i on AF recurrence following CA compared with non-SGLT2i. The primary outcome was the recurrence of AF by the final follow-up reported in each study. Secondary outcomes include AF recurrence by the first follow-up within 12 to 24 months and follow-up intervals (6, 12, 18, 24, and 36 to 42 months) post-ablation, multivariate risk of AF recurrence, and the effect on left atrial diameter (LAD) (less than 45 mm vs. greater than or equal to 45 mm). For risk of bias (ROB) analysis, the NIH ROB and Cochrane ROB2 tool were used. All statistical, heterogeneity, and sensitivity analyses were conducted using Cochrane Review Manager. A random-effect model was employed for all pooled statistical analyses. Results: A total of nine studies, two RCTs and seven retrospective studies, were included (N = 6874) for the primary outcome. Compared to non-SGLT2i (N = 3693), SGLT2i (N = 3181) significantly decreased AF recurrence by the final follow-up (OR = 0.62; 95% CI: 0.45–0.85; p = 0.008). For secondary outcomes, SGLT2i significantly reduced AF recurrence by the first follow-up within 12 to 24 months post-ablation (OR = 0.58; p = 0.0001) and by the different follow-up periods, 6-month (OR = 0.53; p = 0.02), 12-month (OR = 0.56; p = 0.0001), 18-month (OR = 0.55; p = 0.01), and 24-month (OR = 0.60; p = 0.12) follow-up periods. On the other hand, by 36 to 42 months, SGLT2i was associated with increased risk of AF recurrence (OR = 1.41; p = 0.004). Conclusions: We conclude that SGLT2i demonstrated a reduction in AF recurrence following CA, particularly by 12 to 18 months post-ablation.

22 November 2025 in Cureus
Verified
Journal Article
Open access
PDF file
SCSastry Chamarthi
Sastry Chamarthi
SGSurendra Gupta
Surendra Gupta
VCVenkata Sushma Chamarthi
Venkata Sushma Chamarthi
Throughout human history, respiratory infections have been among the most common illnesses affecting populations worldwide. Respiratory syncytial virus (RSV) is recognized as one of the major pathogens responsible for a significant disease burden in young children and the elderly population, causing lower respiratory tract infections. Initially identified as the chimpanzee coryza virus in the mid-20th century, it was later named human RSV. This review outlines the discovery of RSV, the initial challenges faced in vaccine development, and the evolution of monoclonal antibodies for infants and vaccines for pregnant mothers to prevent RSV infection in infants. Early vaccine trials enhanced respiratory disease and increased mortality among vaccinated infants. There were subsequent failures with live attenuated vaccines. Research turned toward developing the monoclonal antibody palivizumab, which provided the first practical means of protecting high-risk infants against RSV infection. Subsequent advances in monoclonal antibodies, especially nirsevimab, and the advent of the maternal vaccination program with the Bivalent Prefusion F Vaccination have expanded disease prevention to the population level instead of targeting high-risk infants. These advances promise to reduce hospitalizations and severe disease, improving overall community health. Future priorities include ensuring equitable access, maintaining long-term safety surveillance, and integrating RSV prevention into national immunization programs worldwide.

3 November 2025 in European Journal of Medical and Health Sciences
Verified
Journal Article
Open access
PDF file
VCVenkata Sushma Chamarthi
Venkata Sushma Chamarthi
Pediatric obesity affects over 14 million children in the United States, yet primary care providers face the “15-minute conundrum” of delivering effective counseling within standard consultation times. Guidelines emphasize comprehensive family-based interventions and intensive health behavior treatment, requiring at least 26 contact hours; however, time constraints remain a significant barrier to implementation.This review synthesizes evidence from recent studies that support brief structured interventions. Studies, including BMI2 and Obemat 2.0, demonstrate that motivational interviewing, delivered by trained providers, improves body mass index trajectories and weight-related outcomes. Systematic reviews confirm that brief motivational interviewing and behavioral lifestyle interventions provide both practical and cost-efficient approaches in primary care settings.Evidence supports practical strategies, including pre-visit preparation using electronic health record alerts, concise goal-setting focused on achievable targets, and structured post-visit follow-up. Studies have shown that families respond positively to targeted, measurable goals rather than broad lifestyle overhauls. Brief, family centered interventions, delivered consistently, transform the clinical paradox of limited time into meaningful opportunities for behavioral change.